The document discusses several topics related to oncology, including: 1. ASCO guidelines for stage III non-small cell lung cancer adjuvant and neoadjuvant treatment. 2. Recommendations for radiotherapy treatment of heterotopic ossification, a rare condition involving bone formation in soft tissue, most commonly after hip surgery or trauma. 3. Differences between incidental and symptomatic low-grade gliomas, finding that incidental tumors are associated with more favorable prognostic factors and outcomes.

1. DR KANHU CHARAN PATRO
M.D, D.N.B[RT], MBA, FICRO, FAROI, PDCR,
CEPC
JUNE 2023 ISSUE/87th VOLUME
www.facebook.com/oncologycartoons/photos_albums
www.slideshare.net/search/slideshow?searchfrom=header&q=oncology+cartoons

4. ASCO GUIDELINES FOR STAGE III NSCLC ADJUVANT AND NEOADJUVANT
CHARLES B. SIMONE/PRO/2023 16th MAY 2023/LUNG

5. ASCO GUIDELINES FOR STAGE III UNRESECTABLE NSCLC
CHARLES B. SIMONE/PRO/2023 17th MAY 2023/LUNG

6. ASTRO RECOMMENDATIONS FOR SMALL BRAIN METS
DIANA GRISHCHUK/PRO/2023 18th MAY 2023/BRAIN

7. BPM - BRACHIAL PLEXUS METASTASIS IN BREAST CANCER
BORIANA KAMENOVA/INT J CLIN ONCOL/2009 19th MAY 2023/BREAST
1. Brachial plexopathy is a significant cause of morbidity in breast cancer patients.
2. The patients often present with pain that is usually severe and radiating; and
shoulder or arm disability.
3. Radiation was employed induces complete responses . Previously irradiated patients
received PTX, which induced complete remissions

8. DECISION ABOUT LOCAL THERAPY FOR OLIGOMET NSCLC
20th MAY 2023/OLIGO
PUNEETH IYENGAR/PRO/2023

9. SEQUENCING OF LOCALAND SYSTEMICTHERAPY FOR OLIGOMET NSCLC
PUNEETH IYENGAR/PRO/2023 21st MAY 2023/OLIGO

10. TUBERCULAR SPINE VS METASTATIC SPINE
GOOGLE 22nd MAY 2023/BRAIN

11. RADIOTHERAPY FOR HETEROTROPHIC OSSIFICATION
GUNDERSON BOOK 23rd MAY 2023/BENIGN
1. Heterotopic ossification (HO) can appear following trauma or surgery of the hip
(total hip replacement) in roughly 5% to 100% of cases, with varying degrees of
severity
2. Most common current dose/fractionation regimen being 7 Gy in a single fraction.
3. Various authors have pointed out that radiotherapy should be started no later than 72
hours after surgery given an increased risk of HO formation with postoperative treatment
beyond that time frame
Brooker
classification

12. DIFFERENCE BETWEEN INCIDENTAL & SYMPTOMATIC LGG
MATTHIAS DEMETZ/JOURNAL OF NEURO-ONCOLOGY/2023 24th MAY 2023/BRAIN
1. Incidental LGG were associated with favorable
prognostic features like lower mitotic activity,
lack of anaplasia and presence of IDH1
mutation.
2. These patients had better pre- and
postoperative performance.
3. The probability of total resection without
causing permanent neurological deficits was
high.
4. Consequently, patients with iLGG compared to
sLGG showed 7 times more favorable PFS and 5
times more favorable OS hazards.
SYMPTOMGENOMICS

14. MUTATION AND LOCATION ASSOCIATION IN MENINGIOMA
ALPER DINCER/JOURNAL OF NEURO-ONCOLOGY/2023 26th MAY 2023/BRAIN

15. Embryology, genomics and therapeutic interventions of meningiomas
JACOB A. PAWLOSKI/INT. J. MOL. SCI. /2021 27th MAY 2023/BRAIN

16. GENETIC ALTERATIONS-LOCATTION-GRADING-THERAPEUTICS IN MENINGIOMAS
JACOB A. PAWLOSKI/INT. J. MOL. SCI. /2021 28th MAY 2023/BRAIN

17. Cancer Predisposition Syndromes and Associated CNS Tumors
JACOB A. PAWLOSKI/INT. J. MOL. SCI. /2021 29th MAY 2023/BRAIN

18. BRAF mutations and fusions by tumor histology and tumor
location in pediatric low-grade gliomas.
Fatema Malbari/PAEDIATRIC ONCOLOGY/2019 30th MAY 2023/BRAIN

19. WWW.123RF.COM 31st MAY 2023/PUBLIC
STOP SMOKING AND SAVE YOUR FAMILY

20. SHIRAN SUN/GREEN/2023 1st JUNE 2023/ H & N
Sinonasal mucosal melanoma: is there a
need for elective neck irradiation?

21. DAVID CIBULA/GREEN/2023 2nd JUNE 2023/CERVIX
Items to be included in the pathology
report of carcinoma cervix

22. DAVID CIBULA/GREEN/2023 3rd JUNE 2023/CERVIX
FERTILITY SPARING PROCEDURES IN CA. CERVIX

23. DAVID CIBULA/GREEN/2023 4th JUNE 2023/CERVIX
Management of Distant recurrent and metastatic CA cervix

24. DAVID CIBULA/GREEN/2023 5th JUNE 2023/CERVIX
FERTILITY SPARING MANAGEMENT OF CANCER CERVIX

25. DAVID CIBULA/GREEN/2023 6th JUNE 2023/CERVIX
MANAGEMENT OF CANCER CERVIX IN PREGNANCY

26. DAVID CIBULA/GREEN/2023 7th JUNE 2023/CERVIX
Hysterectomy specimen with incidental cervical cancer

27. DAVID CIBULA/GREEN/2023 8th JUNE 2023/CERVIX
MANAGEMENT OF RECURRENT CERVICAL CANCER

28. NINA-SOPHIE/GREEN/2023 9th JUNE 2023/PROSTATE
ESTRO-ACROP recommendations duration of ADT with EBRT in prostate ca.
1. No additional ADT is recommended for low-risk prostate cancer patients, whereas for
intermediate- and high-risk patients four to six months and two to three years of ADT are
recommended.
2. Likewise, patients with locally advanced prostate cancer are recommended to receive ADT
for two to three years and when 2 high-risk factors (cT3-4, ISUP grade 4 or PSA 40 ng/ml)
or cN1 is present ADT for three years plus additional Abiraterone for two years is
recommended.
3. For postoperative patients no ADT is recommended for adjuvant EBRT in pN0 patients
whereas for pN1 patients adjuvant EBRT with long-term ADT is performed for at least 24 to
36 months.
4. In the setting of salvage EBRT ADT is performed in biochemically persistent PCa patients
with no evidence of metastatic disease.
5. Long-term ADT (24 months) is recommended in pN0 patients with high risk of further
progression (PSA 0.7 ng/ml and ISUP grade group 4) and a life expectancy of over ten
years, whereas short-term ADT (6 months) is recommended in pN0 patients with lower
risk profile(PSA < 0.7 ng/ml and ISUP grade group 4).
6. Patients considered for ultra-hypofractionated EBRT as well as patients with image based
local recurrence within the prostatic fossa or lymph node recurrence should participate in
appropriate clinical trials evaluating the role of additional ADT

29. ADAURA TRIAL UPDATE
ROY S HERBST/JCO/2023 10th JUNE 2023/LUNG
1. At data cutoff (April 11, 2022), in stage II-IIIA disease, median follow-up was 44.2 months (osimertinib) and
19.6 months (placebo); the DFS HR was 0.23 (95% CI, 0.18 to 0.30); 4-year DFS rate was 70% (osimertinib)
and 29% (placebo).
2. In the overall population, DFS HR was 0.27 (95% CI, 0.21 to 0.34); 4-year DFS rate was 73% (osimertinib) and
38% (placebo).
3. Fewer patients treated with osimertinib had local/regional and distant recurrence versus placebo.
4. CNS DFS HR in stage II-IIIA was 0.24 (95% CI, 0.14 to 0.42).
5. The long-term safety profile of osimertinib was consistent with the primary analysis

30. PROSPECT TRIAL RECTUM - PREOP TREATMENT
DEBORAH SCHRAG/ NEJM/2023 11th JUNE 2023/RECTUM
Locally advanced rectal cancer who were eligible for sphincter-sparing surgery, preoperative FOLFOX was
noninferior to preoperative chemoradiotherapy with respect to disease-free survival.
From June 2012 through December 2018, a total of 1194 patients underwent randomization
and 1128 started treatment; among those who started treatment
The groups were similar with respect to overall survival (hazard ratio for death, 1.04; 95% CI, 0.74 to 1.44) and local
recurrence (hazard ratio, 1.18; 95% CI, 0.44 to 3.16). In the FOLFOX group, 53 patients (9.1%) received preoperative
chemoradiotherapy and 8 (1.4%) received postoperative chemoradiotherapy

31. SHAPE TRIAL CERVIX – LESSER IS SAFER
https://dailynews.ascopubs.org/ 12th JUNE 2023/CERVIX

32. CON-CERV TRIAL CERVIX – LESSER IS SAFER
KATHLEEN M SCHMELER/BMJ/2021 13th JUNE 2023/CERVIX
Eligibility criteria included:
1. FIGO 2009 stage IA2–IB1 cervical carcinoma;
squamous cell (any grade) or
adenocarcinoma (grade 1 or 2 only)
histology
2. tumor size <2 cm by physical examination
and/or imaging studies;
3. No lymphovascular space invasion;
4. Negative imaging for metastatic disease with
CT scan,
5. MRI, and/or positron emission tomography
scan; (6) depth of invasion <10mm
6. Conization margins and endocervical
curettage negative for malignancy and high-
grade dysplasia.
7. A negative
8. margin was defined as no invasive cancer
within 1.0mm of both
9. the endocervical and ectocervical margins
and no adenocarcinoma in situ, cervical
intraepithelial neoplasia 2 or 3 at the inked
or cauterized margin.
10. Inclusion criteria 6 and 7 were added after
the first year of the study as described in the
Results section

33. BRAZILIAN PROOF OF CONCEPT TRIAL CERVIX
Carneiro VCG, et al. Int J Gynecol Cancer 2023 14th JUNE 2023/CERVIX
1. Simple hysterectomy is safe and
potentially non-inferior to modified radical
hysterectomy in patients with early-stage
cervical cancer ≤2 cm.
2. The non-radical approach may be a
substitute for radical hysterectomy for
patients with a low risk of relapse.

34. NATIONAL CANCER SURVIVOR MONTH
Google 15th JUNE 2023/CERVIX